Increasing vaccine potency through exosome antigen targeting

Vaccine

Volumn 29, Issue 50, 2011, Pages 9361-9367

  Hartman, Zachary C ^a   Wei, Junping ^a   Glass, Oliver K ^a   Guo, Hongtao ^a   Lei, Gangjun ^a   Yang, Xiao Yi ^a   Osada, Takuya ^a   Hobeika, Amy ^a   Delcayre, Alain ^c   Le Pecq, Jean Bernard ^c   Morse, Michael A ^b   Clay, Timothy M ^a,b   Lyerly, Herbert K ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ExoThera LLC   (United States)

Author keywords

Adenovirus vectors; C1C2 domain; Cancer vaccines; CEA; Exosomes; HER2; Tumor antigens

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN LACTADHERIN FUSION PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER 2 LACTADHERIN FUSION PROTEIN; HYBRID PROTEIN; LACTADHERIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER PATIENT; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG POTENCY; EXOSOME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, SURFACE; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; EXOSOMES; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MILK PROTEINS; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 80855144189     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.133     Document Type: Article

References (26)

1. Delcayre A., Estelles A., Sperinde J., Roulon T., Paz P., Aguilar B., et al. Exosome display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol Dis 2005, 35(2):158-168.
2. Théry C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2(8):569-579.
3. Finn O.J. Cancer immunology. N Engl J Med 2008, 358(25):2704-2715.
4. Steer H.J., Lake R.A., Nowak A.K., Robinson B.W.S. Harnessing the immune response to treat cancer. Oncogene 2010, 29:6301-6313.
5. Finn O.J., Edwards R.P. Human papillomavirus vaccine for cancer prevention. N Engl J Med 2009, 361:1899-1901.
6. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3:360-441.
7. Pejawar-Gaddy S., Finn O.J. Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 2008, 67(2):93-102.
8. Oshima K., Aoki N., Kato T., Kitajima K., Matsuda T. Secretion of a peripheral membrane protein, MFG-E8, as a complex with membrane vesicles. Eur J Biochem 2002, 269(4):1209-1218.
9. Zeelenberg I.S., Ostrowski M., Krumeich S., Bobrie A., Jancic C., Boissonnas A., et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 2008, 68(4):1228-1235.
10. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998, 95(5):2509-2514.
11. Hartman Z.C., Wei J., Osada T., Glass O., Lei G., Yang X.Y., et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicity and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res 2010, 16(5):1466-1477.
12. Taylor D.D., Zacharias W., Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol Biol 2011, 728:235-246.
13. Lamparski H.G., Metha-Damani A., Yao J.Y., Patel S., Hsu D.H., Ruegg C., et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002, 270(2):211-226.
14. Denzer K., Kleijmeer M.J., Heijnen H.F., Stoorvogel W., Geuze H.J. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000, 113:3365-3374.
15. Lin L., Huai Q., Huang M., Furie B., Furie B.C. Crystal structure of the bovine lactadherin C2 domain, a membrane binding motif, shows similarity to the C2 domains of factor V and factor VIII. J Mol Biol 2007, 371(3):717-724.
16. Bardelle C., Furie B., Furie B.C., Gilbert G.E. Membrane binding kinetics of factor VIII indicate a complex binding process. J Biol Chem 1993, 268(12):8815-8824.
17. Théry C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9(8):581-593.
18. Viaud S., Terme M., Flament C., Taieb J., André F., Novault S., et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 2009, 4(3):e4942.
19. Koga K., Matsumoto K., Akiyoshi T., Kubo M., Yamanaka N., Tasaki A., et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res 2005, 25:3703-3708.
20. Clayton A., Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005, 34(3):206-213.
21. Zhang H.G., Grizzle W.E. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011, 17(5):959-964.
22. Delcayre A., Shu H., Le Pecq J.B. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway. Expert Rev Anticancer Ther 2005, 5(3):537-547.
23. Rountree R.B., Mandl S.J., Nachtwey J.M., Dalpozzo K., Do L., Lombardo J.R., et al. Cancer Res. 2011, 71(15):5235-5244.
24. Cubillos-Zapata C., Guzman E., Turner A., Gilbert S.C., Prentice H., Hope J.C., et al. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predicts enhanced immunogenicity in vivo. J Virol 2011, 85(18):9385-9394.
25. Barefoot B., Thornburg N.J., Barouch D.H., Yu J.S., Sample C., Johnston R.E., et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 2008, 26(48):6108-6118.
26. Rock K.L., Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005, 207:166-183.